Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of...

34
1 Curriculum Vitae Manish Kohli, MD Professor of Oncology Mayo Clinic College of Medicine Consultant Division of Oncology Department of Oncology and Department of Urology Mayo Clinic 200 1st Street Southwest Rochester, Minnesota 55905 (507) 293-0566 (Work) [email protected] Academic Appointments and Positions Consultant 06/2011 – Present Division of Medical Oncology Department of Oncology and Department of Urology Mayo Clinic, Rochester, Minnesota Professor of Oncology 4/2016 – Present Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota Associate Professor of Oncology 12/2008 – 4/2016 Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota Senior Associate Consultant (Joint Appointment) 06/2008 –06/2011 Division of Medical Oncology Department of Oncology and Department of Urology Mayo Clinic, Rochester, Minnesota Co-Director, Inpatient Oncology Services 05/2006 – 06/2008 Strong Memorial Hospital, Rochester, New York Associate Professor of Medicine - Tenured 07/2005 University of Arkansas for Medical Sciences, Little Rock, Arkansas Associate Professor of Medicine and Urology 07/2005 University of Rochester Medical Center, Rochester, New York Research Advisor/Head of Hematology Oncology 11/2002 – 06/2005 Fellowship Research University of Arkansas for Medical Sciences, Little Rock, Arkansas

Transcript of Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of...

Page 1: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

1

Curriculum Vitae

Manish Kohli, MD

Professor of Oncology Mayo Clinic College of Medicine

Consultant

Division of Oncology Department of Oncology and Department of Urology

Mayo Clinic

200 1st Street Southwest Rochester, Minnesota 55905

(507) 293-0566 (Work) [email protected]

Academic Appointments and Positions

Consultant 06/2011 – Present Division of Medical Oncology Department of Oncology and Department of Urology Mayo Clinic, Rochester, Minnesota Professor of Oncology 4/2016 – Present Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota Associate Professor of Oncology 12/2008 – 4/2016 Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota Senior Associate Consultant (Joint Appointment) 06/2008 –06/2011 Division of Medical Oncology Department of Oncology and Department of Urology Mayo Clinic, Rochester, Minnesota Co-Director, Inpatient Oncology Services 05/2006 – 06/2008 Strong Memorial Hospital, Rochester, New York Associate Professor of Medicine - Tenured 07/2005 University of Arkansas for Medical Sciences, Little Rock, Arkansas Associate Professor of Medicine and Urology 07/2005 University of Rochester Medical Center, Rochester, New York Research Advisor/Head of Hematology Oncology 11/2002 – 06/2005 Fellowship Research University of Arkansas for Medical Sciences, Little Rock, Arkansas

Page 2: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

2

Staff Physician 09/1999 – 06/2005 Central Arkansas Veterans Healthcare System, Little Rock, Arkansas Assistant Professor of Medicine – Tenure Track 09/1999 – 06/2005 University of Arkansas for Medical Sciences, Little Rock, Arkansas

Professional Education

Certification in Clinical Trials Concentration 06/2014 – 6/2015 Global Clinical Scholars Research Training Program Harvard Medical School, Office of Global Education Boston, Massachusetts Fellow, Hematology/Oncology 07/1996 – 6/1999 University of Arkansas for Medical Sciences Resident, Internal Medicine 07/1993 – 6/1996 Cook County Hospital MB BS, Medicine/Surgery 1985 – 1990 Maulana Azad Medical College University of Delhi

Board Certifications, Honors and Awards

American Board of Internal Medicine (ABIM) Hematology 2001 – Present Medical Oncology 2000 – 2010 Medical Oncology Recertification 2010 – Present Internal Medicine 1996 – Present Challenge Award Honoree 2014 Prostate Cancer Foundation (PCF) “Movember” Challenge Award Honoree 2015 Prostate Cancer Foundation (PCF) Excellence in Teaching Mayo Clinic Rochester 2013 – 2014

Department of Internal Medicine Certificate Of Appreciation for Strategic Alliance with 03/2013 Mayo Clinic Cancer Center and Comprehensive Cancer Center Seoul National University, Bandung Hospital Mayo Clinic Quality Academy Bronze Level Certification 06/2012

Mayo Clinic Quality Fellow

Page 3: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

3

Selected Attendee Randomized Clinical Trials Course 04/2003 VA Cooperative Studies Program Chicago, Illinois Employee MD of the Year 01/2003 Hematology/Oncology Central Arkansas Veterans Letter of Appreciation 01/2003 Streamlining Guidelines of PSA-Based Practice in Nationwide Veteran Population VA National Headquarters Best Intern of the Year 01/1993 – 01/1994 Internal Medicine Cook County Hospital

Licensure

Minnesota Medical License – 50887 2008 – Present

Professional Memberships & Activities

American Society of Clinical Oncology – Member 03/2000 – Present India Chamber of Commerce – Healthcare Sector - Advisor 2011 – Present American Association for Cancer Research – Member 07/2007 – Present The Minnesota Society of Clinical Oncology-Board Member at Large 08/2014 – Present State Affiliate of the American Society of Clinical Oncology Indian Chamber of Commerce, Health Advisor 05/2015 – Present National Bone Marrow Donor Society – Member & Organizer 04/2009 United States Department of Defense – Member & Peer Review 01/2007- 12/2008 University of Rochester Medical Center – Co-Director of In-Patient

Oncology Services Strong Memorial Hospital Salvation Army, Little Rock Medical Camp – Organizer 01/2003 09/2002 05/2002

Committee Memberships & Other Activities AskMayoExpert – Member 01/2009 – Present AskMayoExpert Committee (Medical Oncology Section) Physician Member 2010 – Present

Page 4: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

4

Mayo Clinic Institutional Review Board – Member 10/2013 – Present Rochester, Minnesota Harvard Medical Alumni Association – Member 06/2014 – Present Boston, Massachusetts Harvard Alumni Association – Member 06/2014 – Present Boston, Massachusetts Mayo Clinic Cancer Center GU Disease-Specific 06/2008 – 09/2013 Working Group – Member & Chair Rochester, Minnesota Mayo Clinic Cancer Center 3-Site GU Disease Oriented Group 06/2008 – 09/2013 Co-Chair Rochester, Minnesota Mayo Clinic Alumni Association – Member

Journal Editorial Responsibilities Invited Ad-Hoc Reviewer Cancer Investigation 10/2007 Journal of Men’s Health 02/2011 Journal of Men’s Health 04/2011 Clinical Advances in Hematology & Oncology 12/2011 Asian Journal of Andrology 08/2012 OncoTargets and Therapy 09/2012 Cancer 2012 European Urology 06/2015 European Urology 08/2015 OncoTarget 11/2015 Frontier in Pharmacogenetics and Pharmacogenomics – Review Editor 07/2013 – Present Mayo Clinic Proceedings – Section Editor 01/2011 – Present Member, Editorial Board- Journal of International Medical Sciences 04/02/2012 – Present Academy (JIMSA)

Educational Activities

Curriculum/Course Development

Friday Fellows' Medical Oncology Didactic Conference 10/2005 – 06/2008 Faculty Organizer, Coordinator, and Preceptor University of Rochester Medical Center, Rochester, New York

Page 5: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

5

Research Advisor and Head of Hematology Oncology Fellowship 11/2002 – 06/2005 Research Curriculum University of Arkansas for Medical Sciences, Little Rock, Arkansas

Teaching

Liquid Biopsy Program in Advanced GU Cancers 02/2016 BMD Urologic Cancer Conference, Mayo Clinic Rochester, MN Research Program in Advanced GU Malignancies 02/2016 Urology Conference, Mayo Clinic Rochester, MN In Search of Response Biomarkers in Advanced Prostate Cancer 02/2016 Therapeutics Oncology Conference, Mayo Clinic Rochester, MN ACCP Prostate Cancer Course 03/2015 Mayo Clinic, Rochester, Minnesota Renal Cell and Bladder Cancer Management in 2014 08/2014 Mayo Clinic Hematology/Oncology Reviews 2014 How to Use National Datasets 02/2014 Mayo Clinic Department of Medicine Academic Career Development Lunch Session ASCO 2013: Updates in GU Oncology 07/2013 Tuesday Oncology CME Conference Mayo Medical School, Rochester, Minnesota ASCO 2012: Updates in GU Oncology 07/2012 Tuesday Oncology CME Conference Mayo Medical School Rochester, Minnesota Recommendations on PSA Screening for Prostate Cancer 04/2012 Prostate Cancer Support Group Rochester, Minnesota PSA Screening for Prostate Cancer: A Victim of "Discordant Harmony" 12/2011 Internal Medicine Grand Rounds Rochester, Minnesota Management of Prostate Cancer in 2011 12/2011 Medical Oncology Core Curriculum Rochester, Minnesota

Page 6: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

6

GnRH Analogues and Antagonists and Anti-androgens (AAs) in 05/2011 Prostate Cancer Core Curriculum Oncology Fellows Tumor Board Teaching 29-year-old female with upper urinary tract renal urothelial cancer: 05/2011 status of adjuvant therapy GU Tumor Board 63-year-old with de-differentiated prostate cancer vs. 05/2011 small cell lung cancer GU Tumor Board Growing Teratoma Syndrome 04/2011 Mayo Clinic Multidisciplinary GU Tumor Board Prostate Cancer and Bone Metastasis 01/2011 Mayo Clinic Multidisciplinary GU Tumor Board Advanced Prostate Cancer - MAB vs. Salvage Surgery 08/2010 Mayo Clinic Multidisciplinary GU Tumor Board Clinical Trials for IHT vs. Continuous ADT 08/2010 Mayo Clinic Multidisciplinary GU Tumor Board Renal Medullary Carcinoma 10/2009 Mayo Clinic Multidisciplinary GU Tumor Board Papillary Renal Cell Carcinoma and Colon Cancer 07/2009 Mayo Clinic Multidisciplinary GU Tumor Board Prostate Cancer Biochemical Relapse 07/2009 Mayo Clinic Multidisciplinary GU Tumor Board Hematology/Oncology Update 07/2009 Mayo Clinic 19th Annual Hematology/Oncology Reviews Fellows Board Review Course 06/2009 Mayo Medical School Metastatic Urothelial Carcinoma status post Chem-XRT-Surgery 06/2009 Mayo Clinic Multidisciplinary GU Tumor Board Metastatic Renal Cell Carcinoid 06/2009 Mayo Clinic Multidisciplinary GU Tumor Board Renal Neuroendocrine Tumors 06/2009 Mayo Clinic Multidisciplinary GU Tumor Board

Page 7: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

7

Papillary Renal Cell Cancers 05/2009 Mayo Clinic Multidisciplinary GU Tumor Board Prostate Adenocarcinoma 03/2009 Mayo Clinic GU Multidisciplinary GU Tumor Board Metastatic Renal Cell Carcinoma 03/2009 Mayo Clinic Multidisciplinary GU Tumor Board Cancer - Two Hits 01/2009 Mayo Clinic Multidisciplinary GU Tumor Board Skeletal Lesions Post Nephrectomy 01/2009 Mayo Clinic Multidisciplinary GU Tumor Board Post-Nephrectomy Occurrence 01/2009 Mayo Clinic Multidisciplinary GU Tumor Board Mature Teratoma with Enteric-like Adenocarcinoma 11/2008 Mayo Clinic Multidisciplinary GU Tumor Board Urothelial Cancer – Overview 11/2008 Mayo Clinic Multidisciplinary GU Tumor Board Biochemical Recurrence Post Primary Prostate Therapy 10/2008 Mayo Clinic Multidisciplinary GU Tumor Board Metastatic Renal Cell Cancer status post Metastasectomy 10/2008 Mayo Clinic Multidisciplinary GU Tumor Board Mayo Clinic Multidisciplinary GU Tumor Board 07/2008 – Present ACS certified (Cases presented by faculty for resident/fellow teaching) Mayo Medical School Introduction to Clinical Medicine II 1999 – 2005 Medical student preceptorships University of Rochester Medical Center, Rochester, New York

Mentorship

Zhang, Ben (Oncology Fellow) 02/2015 Presented ASCO GU Symposium "Germline predictors for survival in

castrate resistant prostate cancer" Shenoy, Neeraj (Oncology Fellow) 6/2015 MicroRNA profiling for treatment outcomes in Advanced Prostate Cancer

Page 8: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

8

Kochuparambil, Samith T (Hematology/Oncology Fellow) 01/2014 Awarded competitive $5000 Medical Oncology Research grant; Publication

"Germline markers for predicting ADT response"; Presented Poster at ASCO GU Symposium 2015 “Germline predictors of

ADT response in hormone sensitive prostate cancer" Haley, Charlotte (Research Trainee) 09/2013 – 05/2014 Selected to attend medical school at University of Limmerick, Ireland (2014) Nandy, Debashis (Research Technician) 04/2013 – 06/2015 Bevan, Graham (Research Assistant) 04/2012 – 02/2013 Selected to attend medical school at University of Rochester, NY (2013) Block, Matthew S (Hematology/Oncology Fellow) 01/2011 Publication "Clinical Hypothyroidism in a Renal Cell Carcinoma Patient

Treated with Sorafenib." Clinical Advances in Hematology & Oncology Verdoorn, Brandon P (Internal Medicine Resident) 01/2010 Awarded competitive $5000 Medical Oncology Research grant. Publication "An observational study of plasma vascular endothelial growth

factors (VEGF) A and D expression in non-localized prostate cancer" Journal of Men's Health. 2012; 9(3): 182-189

AliKhan, M (Fellow) 01/2005 "Randomized Phase III Trial of High-Dose Interleukin-2 versus

Subcutaneous Interleukin-2 and Interferon in Patients with Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology

Challagundla, S (Hematology/Oncology Fellow) 01/2005 Publication "Orbital Metastasis from Prostate Cancer: An Atypical Case

of Neuro-Endocrine De-Differentiation During Progression from Hormone Sensitive to Refractory Stage," Clinical Advances in Hematology and Oncology

Midathada, M (Hematology/Oncology Fellow) 01/2005 Publication "Ocular Melanoma Versus Ocular Metastasis: A Diagnostic

Dilemma," Clinical Advances in Hematology and Oncology Alikhan, Mir (Hematology/Oncology Fellow) 02/2004 Selected to present poster at the National Fellow Oncology Conference,

"Prognostic value of plasma VEGF in advanced prostate cancer: an exploratory analysis." Also, publication "Randomized Phase III Trial of High-Dose Interleukin-2 versus Subcutaneous Interleukin-2 and Interferon in Patients with Metastatic Renal Cell Carcinoma" Journal of Clinical Oncology

Midathada, M (Hematology/Oncology Fellow) 01/2004 Awarded Merit Award for presentation at ASCO 2004 for her poster, "Role

of androgen deprivation en EGFR and Her-2/neu gene expression patterns in prostate cancer."

Page 9: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

9

Phooskoru V, Alikhan Mir (Hematology/Oncology Fellow) 01/2004 "Randomized trial of adjuvant therapy in colon carcinoma: 10-year results

of NSABP protocol C-01," correspondence, Journal of National Cancer Institute

McKenzie, Kyle M (Internal Medicine Resident) Publication: Predicting Time to Castration Resistance in Hormone Sensitive Prostate Cancer by a Personalization Algorithm Based on a Mechanistic Model Integrating Patient Data. The Prostate. 2015 Sep 30

Extramural Presentations

Invited/Proffered Presentations

Ethical Considerations in Pregnancy Related Research Medical University Kawagoe, Japan 12/2015 Management of Hepatocellular Cancer and Liver Metastasis Medical College and Hospital Ludhiana, India 02/2014 Molecular Genetics in Prostate Cancer 02/2014 Post Graduate Institute of Medical Education and Research Chandigarh, Punjab, India Updates in the treatment of Metastatic prostate cancer and metastatic kidney cancer International Conference of International Medical Sciences Academy (Affiliated to Council for International Organizations of Medical Sciences, WHO) Geneva, Switzerland 10/2014 Genomic Application in Prostate Cancer 01/2014 Seoul, South Korea Advances in Cancer Genetics Applied to Genito-Urinary Oncology RajaRajeshwari Medical College and Hospital, Bangalore & The International Medical Sciences Academy 10/2013 Distinguished International Faculty Presenter Eight ISABS Conference in Forensic Anthropological and Medical Genetics Mayo Clinic Lectures in Translational Medicine 06/2013 Split, Croatia Prostate Cancer Medically Optimized Genome Enhanced Therapy in 05/2013 Castrate-Resistant Stage (PROMOTE) Genome-Based Medicine in Advanced Prostate Cancer: A Center for

Individualized Medicine Initiative Prostate Cancer Support Group

Page 10: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

10

Coagulation and Pregnancy and Regional Anesthesia/Analgesia Siriraj Hospital, Mahidol University Bangkok, Thailand 02/2013 Updates in Genitourinary Oncology 07/2012 Apollo Hospital New Delhi, India Medical Advances in Advanced Prostate Cancer 03/2012 – 04/2012 Apollo Indraprasta Hospital New Delhi, India Recent Advances in the Management of Castrate Resistant 02/2012 Prostate Cancer (CRPC): 2012 Mayo-Ramathibodi Hospital Conference Bangkok, Thailand Chemotherapy for Bladder Cancer: From the Medical Oncology 02/2012 Viewpoint Mayo-Ramathibodi Hospital Conference Bangkok, Thailand The Prognostic Influence of Inherited Polymorphisms on 05/2008 Prostate Cancer Outcomes AACR Special Conference "Candidate Pathway and Whole Genome Scans" An Exploratory Analysis of the R250W Polymorphism in the KLK2 04/2007 Gene as a Prognostic Marker in Prostate CancerPlenary Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment Conference AACR Modulation of Coagulation/Angiogenesis Pathways in Preventing 09/2004 Prostate Tumor Growth Division of Hematology/Oncology Boston School of Medicine, Boston University Boston, Massachusetts Angiogenesis Treatments in Cancer 07/2004 Advanced Cancer Treatment, Research, and Education Center Bombay, India An Update on Advanced Prostate Cancer Management 07/2004 Maulana Azad Medical College, University of Delhi, India Anemia in the ICU 04/2003 Faculty Presenter Stead Symposium

Page 11: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

11

Oral Presentations In search of a Response Biomarker in Advanced Prostate 03/2016 Cancer Therapeutics University of California Davis Davis, California Ethical Considerations in Pregnancy Related Research 12/2015 Saitama Medical University Kawagoe, Japan

Biomarker development in advanced prostate cancer and 12/2015 clinical applications University of Illinois at Urbana-Champaign Urbana, Illinois

Value of Blood Banking in India 05/2015 Invited Presentation by Consular General of India Presented at the Life Sciences Summit Indian Consulate Chicago, Illinois Prostate Cancer Medically Optimized Genome-Enhanced 05/2015 Therapy (PROMOTE) Park Nicolett Health System Minneapolis, Minnesota Initiated Hospital to Hospital Collaboration between Mayo 11/2014 Clinic Cancer Center and Seoul National Hospital MOU between MCCC and SNU signed for collaborative research in cancer Bundang Hospital South Korea Prostate Cancer Medically Optimized Genome-Enhanced 07/2014 Therapy (PROMOTE) Evanston, Illinois Prostate Cancer Medically Optimized Genome-Enhanced 04/2014 Therapy (PROMOTE) La Crosse, Wisconsin Prostate Cancer Medically Optimized Genome-Enhanced 03/2014 Therapy (PROMOTE) Mason City, Iowa Prostate Cancer Medically Optimized Genome-Enhanced 09/2013 – 10/2013 Therapy (PROMOTE) Rochester, Minnesota Prostate Cancer Medically Optimized Genome-Enhanced 08/2013 Therapy (PROMOTE) Evanston, Illinois

Page 12: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

12

Prostate Cancer Medically Optimized Genome-Enhanced 06/2013 Therapy (PROMOTE) Grand Forks & Bismarck, North Dakota Prostate Cancer Medically Optimized Genome-Enhanced 05/2013 Therapy (PROMOTE) Scottsdale, Arizona Prostate Cancer Medically Optimized Genome-Enhanced 05/2013 Therapy (PROMOTE) Sterling, Illinois Prostate Cancer Medically Optimized Genome-Enhanced 04/2013 Therapy (PROMOTE) University of Minnesota Minneapolis, Minnesota Prostate Cancer Medically Optimized Genome-Enhanced 03/2013 Therapy (PROMOTE) Eau Claire, Wisconsin Prostate Cancer Medically Optimized Genome-Enhanced 02/2013 Therapy (PROMOTE) Mankato, Minnesota ASCO 2012: Updates in Genitourinary Oncology 07/2012 Mayo Clinic Oncology Review Minneapolis, Minnesota Evaluation of ERG Expression in Metastatic Carcinoma of the Prostate 03/2012 2012 USCAP Annual Meeting Vancouver, British Columbia, Canada Subcutaneous metastases from renal cell cancer 11/2011 GU Oncology Conference Metastatic renal cell cancer versus primary pulmonary diseases 11/2011 GU Oncology Conference Sarcomatoid renal cell cancer management 11/2011 GU Oncology Conference Complex left renal cyst and microscopic anemia-diagnostic dilemma 11/2011 GU Oncology Conference Adrenal cortical carcinoma versus metastatic renal cell cancer: 09/2011 a diagnostic dilemma GU Tumor Board

Page 13: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

13

What is New in the Treatment of Prostate Cancer 08/2011 21st Annual Mayo Clinic Hematology/Oncology Review Amelia Island, Florida Kidney Cancer Management: Overview of Therapeutic Approaches 07/2011 Alaska Native Medical Center & Mayo Cancer Center Conference Anchorage, Alaska Variation in UDP glucouronyltransferase (UGT) genes associated with 04/2011 prostate cancer mortality 102nd AACR Annual Meeting Testicular Cancer -- When is Chemotherapy Indicated 07/2010 20th Annual Mayo Clinic Hematology/Oncology Reviews GU ASCO Update 08/2009 American Society of Clinical Oncology Hematology/Oncology Update 08/2009 Mayo Clinic 19th Annual Hematology/Oncology Reviews Prostate Cancer Research in Prostate SPORE 03/2009 Patient Education Lecture The Prognostic Influence of Inherited Polymorphisms on 05/2008 Prostate Cancer Outcomes AACR Special Conference "Candidate Pathway and Whole Genome Scans" Sarcomatoid Urothelial Cancer. Management and Case Discussion 05/2005 Cancer Conference Central Arkansas Veterans Healthcare System Tumor Board Cancer Coagulation. A Tale of a Two-Headed Hydra 04/2005 Internal Medicine Grand Rounds, Department of Medicine University of Arkansas for Medical Sciences Little Rock, Arkansas Management of Advanced TCC Bladder with Renal Failure: 03/2005 Role of Dialysis in Chemotherapy of Bladder Cancer Conference Central Arkansas Veterans Healthcare System Tumor Board Angiogenesis Therapies in Cancer: A False Horizon or Mantra 09/2003 for Success Internal Medicine Grand Rounds, Department of Medicine University of Arkansas for Medical Sciences Little Rock, Arkansas De-differentiated Adenocarcinoma of the Prostate Cancer Conference 08/2003 Central Arkansas Veterans Healthcare System Tumor Board

Page 14: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

14

Questionable Pancreatic Mass Management Cancer Conference 11/2002 Central Arkansas Veterans Healthcare System Tumor Board Metastatic Prostate Cancer vs. Rectal Cancer Conference 11/2002 Central Arkansas Veterans Healthcare System Tumor Board Recurrent Prostate Carcinoma and Metastatic Renal Cell Carcinoma 07/2002 Cancer Conference Central Arkansas Veterans Healthcare System Tumor Board Metastatic Renal Cell Carcinoma Cancer Conference 07/2002 Central Arkansas Veterans Healthcare System Tumor Board Metastatic Melanoma and Metastatic Prostate Cancer Conference 06/2002 Central Arkansas Veterans Healthcare System Tumor Board Transitional Cell Carcinoma Cancer Conference 04/2002 Central Arkansas Veterans Healthcare System Tumor Board Angiogenesis in Advanced Prostate Cancer Conference 04/2002 Central Arkansas Veterans Healthcare System Tumor Board High-Grade Astrocytoma Cancer Conference 02/2002 Central Arkansas Veterans Healthcare System Tumor Board Testicular Cancer Conference 01/2002 Central Arkansas Veterans Healthcare System Tumor Board Controlled Study of Circulating Angiogenic Markers in 2002 “Hormone-Escaping” Advanced Stage Prostate Cancer During Androgen Deprivation Therapy Kohli M, Kaushal V, Spencer HJ, Mehta P 7th National VA Conference Metastatic Renal Cell Carcinoma Cancer Conference 12/2001 Central Arkansas Veterans Healthcare System Tumor Board Merkel Cell Carcinoma and Melanoma Cancer Conference 10/2001 Central Arkansas Veterans Healthcare System Tumor Board Urethral Cancer Conference 07/2001 Central Arkansas Veterans Healthcare System Tumor Board Metastatic Renal Cell Carcinoma and Small Cell Variant Prostate 04/2001 Cancer Conference Central Arkansas Veterans Healthcare System Tumor Board Colon Adenocarcinoma, Renal Cell Carcinoma, and Metastatic Colon 03/2001 Cancer Conference Central Arkansas Veterans Healthcare System Tumor Board

Page 15: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

15

Primary Cancer Conference 01/2001 Central Arkansas Veterans Healthcare System Tumor Board Bladder Cancer Conference 01/2001 Central Arkansas Veterans Healthcare System Tumor Board Prostate Cancer Conference 01/2001 Central Arkansas Veterans Healthcare System Tumor Board Analysis of Prostate Specific Antigen (PSA) Based Practice in 2001 Elderly Veterans’ Population Kohli M, Coke P, Hauer-Jensen M, Hutchins L, Mehta P 6th National VA Conference Rectal Adenocarcinoma Cancer Conference 08/2000 Central Arkansas Veterans Healthcare System Tumor Board Lung Cancer Conference 03/2000 Central Arkansas Veterans Healthcare System Tumor Board

Poster Presentations

Association of androgen receptor V9 (ARV9) mRNA expression 1/2016 in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P) ASCO GU Symposium The association of JAK2 polymorphisms with prognosis in 1/2016 castration-resistant prostate cancer (CRPC) ASCO GU Symposium Androgen Receptor V9 (ARV9) mRNA expression in metastatic tissue 10/2015 is associated with early resistance to Pre-Chemotherapy Abiraterone Acetate/Prednisone (AA/P) 22nd Annual Prostate Cancer Foundation Scientific Retreat

Feasibility Analysis of Pathology and Genetic Yield from a Prospective 10/2015 Trial of Tissue Biopsies in Metastatic Castrate Resistant Prostate Cancer (mCRPC) 22nd Annual Prostate Cancer Foundation Scientific Retreat Impact of biopsy of metastases on circulating tumor cell (CTC) 9/2015 counts in castrate resistant prostate cancer (CRPC 18th ECCO - 40th ESMO European Cancer Congress A molecular and clinico-pathological model for predicting abiraterone 05/2015 acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC) ASCO Annual meeting

Page 16: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

16

Androgen receptor (AR) based biomarker association with response 02/2015 to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC) ASCO GU Symposium Change in Circulating Tumor cell (CTC) counts as predictive marker 02/2015 of response in chemotherapy naïve castrate resistant metastatic prostate cancer (CRPC) treated with abiraterone acetate (AA) ASCO GU Symposium Feasibility Analysis of Pathology and Genetic Yield from a 02/2015 Prospective Trial of Tissue Biopsies in Metastatic Castrate Resistant Prostate Cancer (mCRPC) ASCO GU Symposium Effect of metastatic site biopsy on circulating tumor cell (CTC) count 02/2015 in castrate resistant prostate cancer (CRPC) stage ASCO GU Symposium Neuroendocrine phenotype expression patterns in metastases from 05/2014 advanced prostate cancer ASCO Annual meeting Association of germ-line genetic variation with failure of androgen 05/2013 ablation (AA) in hormone-sensitive advanced prostate cancer ASCO Annual Meeting Association of germ-line genetic variation in the NK3 homeobox 1 02/2013 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC) ASCO GU Symposium Randomized Phase II Trial of Maintenance Sunitinib Versus Placebo 02/2012 Following Response to Chemotherapy (CT) for Patients (pts) with Advanced Urothelial Carcinoma (UC) ASCO GU Symposium Serum proteomics-guided discovery of predictive biomarkers of 02/2012 response to androgen ablation (AA) in prostate cancer ASCO GU Symposium Variation in sex steroid methyl transferases predict efficacy of 02/2012 androgen deprivation therapy (ADT) in advanced prostate cancer ASCO GU Symposium Variation in UDP glucouronyltransferase (UGT) genes associated with 02/2011 prostate cancer mortality ASCO GU Symposium Genetic polymorphism association with hot flashes in prostate cancer 2009 patients initiated on androgen deprivation therapy (ADT) ASCO GU Symposium

Page 17: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

17

Hormonal and chemotherapy effects on plasma VEGF-A and -D in 2009 prostate cancer patients ASCO GU Symposium A cross sectional study of Angiopoietin-1 (Ang-1) in early and 2008 advanced prostate cancer ASCO Annual Meeting Chicago, Illinois Role of Androgen Deprivation in EGFR and Her-2/Neu Gene 2004 Expression Patterns in Prostate Cancer: #9574 Midathada M, Dennis R, Kaushal V, Kohli M Annual Meeting American Society of Clinical Oncology Molecular Targets for Anti-Angiogenesis in Prostate Cancer 2003 Kohli M, Mukunyadzi P, Mehta P, Spencer HJ, Kaushal V Annual Meeting American Society of Clinical Oncology Stage-Specific Expression of Lymphangiogenic Markers in 2003 Prostate Cancer Kaushal V, Mukunyadzi P, Mehta P, Kohli M Annual Meeting American Society of Clinical Oncology Controlled Study of Circulating Angiogenic Markers in 2002 “Hormone-Escaping” Advanced Stage Prostate Cancer During Androgen Deprivation Therapy; #10342 Kohli M, Kaushal V, Spencer HJ, Mehta P Annual Meeting American Society of Clinical Oncology

Bibliography - Peer-reviewed Articles

1. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016 Mar 8 Epub 2016 Mar 08.

2. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol 2016 Feb 29.

3. Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JPA. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. 2016.

4. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L. Plasma extracellular RNA profiles in healthy and cancer patients. Scientific Reports. 2015.

Page 18: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

18

5. Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R,

Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshiboum R, Wang L. Mutational landscapes of sequential prostate metastases and matched patient derived xenografts during Enzalutamide therapy. PLOS ONE. 2015 Dec.

6. Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Agur Z, Kohli M. Predicting Time to Castration Resistance in Hormone Sensitive Prostate Cancer by a Personalization Algorithm Based on a Mechanistic Model Integrating Patient Data. The Prostate. 2015 Sep 30 PMID 264 19619. doi: 10.1002/pros.23099

7. Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV. Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther. 2015; 8:1915-22. Epub 2015 Jul 30. PMID: 26261420 PMCID: 4527520 doi:10.2147/OTT.S86637

8. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46. Epub 2015 Aug 05. PMID:26244877. DOI:10.1056/NEJMoa1503747.

9. Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D,

White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz M, Singal PK, Mulvagh S, Jassal DS. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Aug 15; 309(4):H692-701. Epub 2015 Jun 19. PMID:26092985. DOI:10.1152/ajpheart.00172.2015.

10. Kohli M, Xia S, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun 30; 6(18):16411-21. PMID:25915538.

11. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Wang L, Kohli M. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):33-41. Epub 2014 Aug 14. PMID:25129854. PMCID:4252606. DOI:10.1016/j.eururo.2014.07.035.

12. Thanarajasingam G, Milone M, Kohli M. Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep. 2015; 2015. Epub 2015 May 04. PMID:25939973. DOI:10.1136/bcr-2014-208913.

13. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep; 89(9):1287-306. PMID:25192616. PMCID:4258909. DOI:10.1016/j.mayocp.2014.05.013.

Page 19: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

19

14. Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M,

Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug; 192(2):357-63. Epub 2014 Mar 12. PMID:24631107. DOI:10.1016/j.juro.2014.03.006.

15. Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May; 13(5):1067-77. Epub 2014 Mar 27. PMID:24674886. PMCID:4308972. DOI:10.1158/1535-7163.MCT-13-0699.

16. Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L. ERNA: A graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing. BMC Genomics. 2014; 15(1):176.

17. Vaa B, Kohli M, Price KA, Swetz KM. Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Rep. 2014; 2014. Epub 2014 Jun 11. PMID:24920508. DOI:10.1136/bcr-2013-200137.

18. Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014; 120(5):692-701.

19. Loprinzi PD, Kohli M. Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national U.S. sample. Journal of Physical Activity and Health. 2014; 11(8):1587-92.

20. Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 2014; 5(3):824-40.

21. Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013 Nov 26; 7(11):9518-25. PMID:24274814. PMCID:3894659. DOI:10.1021/nn405674m.

22. Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc. 2013 Jan; 88(1):11-21. PMID:23274016. DOI:10.1016/j.mayocp.2012.10.012.

23. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013; 14:319. Epub 2013 May 10. PMID:23663360. PMCID:3653748. DOI:10.1186/1471-2164-14-319.

24. Qin R, Kohli M. Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Pers. Med. 2013; 10(8):859-69.

Page 20: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

20

25. Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma

without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors. 2013; 5(3):e29. Epub 2013 Jul 05. PMID:24179641. PMCID:3804804. DOI:10.4081/rt.2013.e29.

26. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens health. 2012 Sep 1; 9(3):182-9. PMID:24416090. PMCID:3886726.

27. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87(6):540-7. PMID:22677074. PMCID:3498058. DOI:10.1016/j.mayocp.2012.01.017.

28. Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Mar; 14(2):193-7. Epub 2012 Jan 30. PMID:22286861. PMCID:3338189. DOI:10.1038/aja.2011.101.

29. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87(3):240-6. PMID:22386179. PMCID:3538410. DOI:10.1016/j.mayocp.2011.09.009.

30. Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012:781459. Epub 2012 Aug 22. PMID:22956944. PMCID:3432332. DOI:10.1155/2012/781459.

31. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019. Epub 2012 Feb 22. PMID:22461839. PMCID:3296311. DOI:10.1155/2012/303019.

32. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An oberservational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. Journal of Men's Health. 2012; 9(3):182-189 Epub 2012 Aug 11. DOI:10.1016/j.jomh.2012.04.003.

33. Nabhan M, Kim S, Shah N, Bagniewski S, Shi Q, Karnes RJ, Weight C, Davis B, Kohli M, Tilburt J. The relationship of the intensity of post-treatment PSA surveillance and prostate cancer outcomes: Results from a population-based cohort. Mayo Clinic Proceedings. 2012 (in press).

34. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13(3):365-77. Epub 2011 May 11. PMID:21560017. PMCID:3144372. DOI:10.1208/s12248-011-9279-4.

35. * Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. PMID:21558995.

Page 21: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

21

36. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest. 2011 Jan; 29(1):62-7. PMID:21166500. PMCID:3136353. DOI:10.3109/07357907.2010.535057.

37. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010 Jan; 85(1):77-86. PMID:20042563. PMCID:2800284. DOI:10.4065/mcp.2009.0442.

38. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8. PMID:21178268. PMCID:3982319. DOI:10.3233/CBM-2010-0152.

39. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31. PMID:21234257. PMCID:3019600. DOI:10.4081/rt.2010.e65.

40. Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4. PMID:19219655. DOI:10.1080/07357900802527247.

41. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6. PMID:18091328. DOI:10.1097/01.pai.0000213157.94804.fc.

42. Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U. Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7. PMID:17099632.

43. Kohli M, Schaefer R. Management of solitary palatal metastasis from renal cell carcinoma. Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396. PMID:16835627. DOI:10.1038/ncpuro0536.

44. Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M. Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800. PMID:16834663. DOI:10.1111/j.1442-2042.2006.01405.x.

45. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. PMID:16622120. DOI:10.1093/jnci/djj129.

46. Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58. PMID:17264396.

47. Kaushal V, Kohli M, Richard D, Chiles W, Mukunyadzi P. Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21.

48. Alikhan MA, Spencer HJ, Kohli M. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol. 2005 Sep 1; 23(25):6267-8.

Page 22: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

22

49. Challagundla S, Gokden M, Viswamitra S, Kohli M. Orbital metastasis from prostate cancer: an

atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer. 2005 Sep; 4(2):134-7. PMID:16197616.

50. Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M. Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7. PMID:16167017.

51. Kaushal V, Dennis R, Mukunyadzi P, Siegel E, Johnson D, Kohli M. Stage specific expression of VEGF A and D in prostate cancer. Clin Cancer Res. 2005; 11:1-10.

52. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20. PMID:15470214. DOI:10.1056/NEJMoa041318.

53. Kohli M, Mukunyadzi P, Dennis RA, Johnson DE, Kaushal V. COX-2: an inconsistent therapeutic target in prostate cancer. Uro Oncology. 2004 Sep/Dec; 4(3/4):113-8.

54. Kohli M, Zent C, Hutchins LF, Safar M, Dotson, P, Mehta P. The academic hematology-oncology firm: a model for postgraduate cancer education. J Cancer Educ. 2004 Spr; 19(1):45-9. PMID:15059755.

55. Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. PMID:12805351.

56. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003 Jun; 29(3):301-8. PMID:12888934.

57. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003 Apr; 61(4):765-9. PMID:12670562.

58. Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58. PMID:12699077.

59. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3. PMID:12089240.

60. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5. PMID:11994561.

61. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71. PMID:10832943.

Page 23: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

23

Book Chapters

1. Kohli M, Zhang B, Costello BA. Medical Management of germ cell tumors In: Springer. Germ Cell Tumor 2015 Decmeber. (Forthcoming Book chapter)

2. Goetz MP, Erlichman C, Loprinzi CL, Kohli M. Hormonal agents. In: DeVita VT Jr; Lawrence TS; Rosenberg SA editor. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 10th Edition. Philadelphia: Wolters Kluwer; 2015. p. 278-89. (Book chapter)

3. Kohli M, Lawrence TS, Reddy NM, Chinratanalab W, Goodman SA, Savani BN, Abrams DI, Hochster HS. Principles of antieoplastic therapy. In: Rose MG; et al, editor. Oncology in primary care. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013. p. 217-36. (Book chapter)

4. M Kohli, T Lawrence, S Goodman, B Savani, W Chinratanalab, N Reddy, D Abrams, H Hochster. Principles of Anti-Neoplastic Therapy. In: In MG Rose, VT Devita Jr, TS Lawrence SA Rosenberg. Oncology in Primary Care Philadelphia, PA: Lippincott Williams & Wilkins; 2012. (Book chapter)

5. Goetz MP, Erlichman C, Kohli M, Loprinzi CL. Endocrine manipulation. In: In: DeVita VT Jr; et al, editor. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 508-19. (Book chapter)

6. Goetz MP, Erlichman C, Loprinzi CL, Kohli M. Endocrine Manipulations. In: CANCER: Principles

and Practice of Oncology 2010. (Book chapter)

7. Kohli M, Tindall D. Hormonal Therapy in Prostate Cancer. In: Encyclopedia of Cancer 3rd ed. 2010. (Book chapter)

8. Kohli M, Lipschitz DA, Chatta GS. Impact of nutrition on the age related declines in heamatopoiesis. In: Chernoff R. Geriatric nutrition the health professional’s handbook. 2nd ed. Aspen: Jones & Bartlett Publishers; 1999. (Book chapter)

Editorials

1. Rajkumar SV, Kohli M. Introduction to the Symposium on Neoplastic Hematology and Medical Oncology. Mayo Clin Proc. 2015 Jul; 90(7):848-9. PMID:26141326. DOI:10.1016/j.mayocp.2015.05.003.

2. Kohli M. Does our "flight and fight" response have a link with cancer? Mayo Clin Proc. 2013 Nov; 88(11):1185-7. PMID:24182698. DOI:10.1016/j.mayocp.2013.09.005

Commentaries

1. Tilburt JC, Kim S, Kohli M, Nahbhan M. In reply. Mayo Clin Proc. 2013 Mar; 88(3):308. Epub 2013 Feb 27 PMID:23489461. DOI:10.1016/j.mayocp.2012.12.004.

2. Kohli M, (Expert Commentary). Cabozantinib Promising in Castration-Resistant Prostate Cancer. Clinical Oncology. MAR2013; 08:03.

Page 24: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

24

Letters

1. Kohli M, Loprinzi PD. Serum prostate-specific antigen association with neutrophil counts: results from the National Health and Nutrition Examination Survey 2001-2010. Int J Urol. 2014 Feb; 21(2):224-5. Epub 2013 Aug 01. PMID:23906321. DOI:10.1111/iju.12240.

2. Kohli S, Kohli M. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer: are there implications for blood pressure management in patients receiving chemotherapy? J Clin Oncol. 2006 May 20; 24(15):2399; author reply 2399-400. PMID:16710045. DOI:10.1200/JCO.2006.05.7836.

3. Kohli M. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 2006 Jan 1; 106(1):234-5; author reply 235. PMID:16284988. DOI:10.1002/cncr.21528.

4. Alikhan M, Spencer HJ, Kohli M. High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon. J Clin Oncol. 2005 Sep 1; 23(25):6267-8; author reply 6268-9. PMID:16135500. DOI:10.1200/JCO.2005.01.5099.

5. Alikhan MA, Phooskooru V, Kohli M. Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst. 2004 Dec 1; 96(23):1794; author reply 1794. PMID:15572762. DOI:10.1093/jnci/djh340.

Abstracts

1. Jimenez RE, Abbas J, Cheville JC, Kohli M. Comparative analysis of neuroendocrine phenotype in metastases from advanced prostate cancer and their corresponding primary tumor. Laboratory Investigation 2016 Feb; 96:241A.

2. Zhang BYM, Mahoney DW, Riska SM, Cerhan JR, Teixeira Ribeiro RJ, Medeiros R, Monteiro C, Nogueira A, Mauricio J, Fraga AM, Calais-Da-Silva F, Costello BA, Dronca RS, Pitot HC, Moynihan TJ, Quevedo F, Kohli M. Variation in trmt11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (crpc) patients. J Clin Oncol. 2015 May 20; 33(15).

3. Wang, L, Xia S, Du M, Ditmar R, Yuan T, Guo Y, Wang Y, Lee A, Tschannen M, Worthey E, Jacobs H, Huang CC, Kohli M. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. AACR Annual Meeting. April 2015.

4. Jimenez RE, Sicotte H, Barman P, Sinnwell JP, Eiken PW, Atwell TD, McMenomy BP, Tan W, Wu K, Bryce AH, Ho TH, Pitot HC, Quevedo F, Costello BA, Dronca RS, Moynihan TJ, Wang LW, Qin R, Carlson R, Kohli M. Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mcrpc). J Clin Oncol. 2015 Mar 1; 33(7).

5. Kochuparambil ST, Zhang BY, Riska SM, Mahoney DW, McDonnell S, Lee AM, Quevedo F, Costello BA, Pitot HC, Ribeiro R, Medeiros R, Monteiro C, Nogueira A, Mauricio J, Fraga AM, Da Silva FEC, Cerhan JR, Kohli M. Association of germline variation with androgen ablation (aa) failure in advanced hormone-sensitive prostate cancer (hspc). J Clin Oncol. 2015 Mar 1; 33(7).

Page 25: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

25

6. Kohli M, Eiken PW, McMenomy BP, Atwell TD, Tan W, Qin R, Carlson R, Campion MB, Wang

LW, Costello BA, Pitot HC, Quevedo F, Scheel EA, Ho TH, Bryce AH, Paz-Fumagalli R, Moynihan TJ, Dronca RS, Liu MC. Effect of metastatic site biopsy on circulating tumor cell (ctc) count in castrate resistant prostate cancer (crpc) stage. J Clin Oncol. 2015 Mar 1; 33(7).

7. Kohli M, Wang LG, Sicotte H, Qin R, Carlson R, Eckel-Passow J, Tan W, Wu K, Dehm S, Eiken PW, Jimenez RE, Cernigliaro J, Quevedo F, Costello BA, Pitot HC, Moynihan TJ, Ho TH, Dronca RS, Bryce AH, Wang LW. Androgen receptor (ar) based biomarker association with response to abiraterone acetate/prednisone (aa/p) in metastatic castrate resistant prostate cancer (mcrpc). J Clin Oncol. 2015 Mar 1; 33(7).

8. Petrylak DP, Tagawa ST, Kohli M, Tang SD, Zhang H, Hamid O, Kauh JS, Walgren RA, Chi KN. Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. J Clin Oncol. 2015 Mar 1; 33(7).

9. * Zhang BYM, Riska SM, Mahoney DW, Teixeira Ribeiro RJ, Medeiros R, Monteiro C, Cerhan JR, Costello BA, Dronca RS, Quevedo F, Pitot HC, Moynihan TJ, Mauricio J, Fraga AM, Calais Da Silva FE, Kochuparambil ST, Kohli M. Variation in trmt11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (crpc) patients. J Clin Oncol. 2015 Mar 1; 33(7).

10. Haas NB, Manola J, Flaherty K, Uzzo RG, Atkins MB, Dutcher JP, Wood CG, Kane CJ, Jewett MAS, Coomes B, Matin SF, Kuzel T, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler WM, DiPaola RS. Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. J Clin Oncol. 2015; 33.

11. Kohli M, Qin R, Wang L, Sicotte H, Carlson R, Tan W, Jimenez RE, Wang L, Eckel-Passow J, Costello BA, Pitot HC, Quevedo F, Dronca RS, Wu K, Moynihan TJ, Ho TH, Bryce AH, Atwell TD, McMenomy BP, Dehm S. A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC) J Clin Oncol. 2015; 33.

12. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar RL, Sun Z, Lu Y, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal mir-1290 and mir-375 as prognostic markers in metastatic castrate resistant prostate cancer. Cancer Res. 2014 Oct 1; 74(19).

13. Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M, Wong Y, Hahn NM, Kohli M, Vogelzang N, Cooney M, Dreicer R, Picus J, Shevrin D, Hussain M, Garcia J, Dipaola R. Chemohormonal therapy versus hormonal therapy for hormone naive high volume newly metastatic prostate cancer (prca): ecog led phase iii randomized trial. Ann Oncol. 2014 Sep; 25.

14. Kohli M, Huang XY, Yuan TZ, Sun ZF, Costello BA, Quevedo F, Tan W, Nandy D, Longenbach S, Wang L. Exosomal microrna as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mcrpc). J Clin Oncol. 2014 Feb 1; 32(4).

15. Costello BA, Ho TH, Tan W, Leibovich BC, Castle EP, Parker AS, Dronca RS, Qin R, Kohli M. Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial). J Clin Oncol. 2014; 32:5s.

Page 26: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

26

16. Sweeney C, Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, Wong YN, Hahn NM, Kohli M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garcia JA, DiPaola RS. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol. 2014; 32(5s).

17. Jimenez RE, Nandy D, Qin R, Carlson R, Tan W, Kohli M. Neuroendocrine differentiation patterns in metastases from advanced prostate cancer. J Clin Oncol. 2014; 32(5s suppl). Abstract no. 5085.

18. Kohli M, Nandy D, Haley C, Tan W, Lee A, Cerhan JR, Tindall D, Pathak J, Breitenstein M. Impact of beta-blocker medication use on prostate cancer survival: Results from a single-institution cancer registry. J Clin Oncol 32 (suppl. 2014; abstr e16064).

19. Kohli M, McDonnell S, Bevan G, Riska SM, Costello BA, Longenbach S, Dronca RS, Moynihan TJ, Pitot HC, Quevedo JF, Cerhan JR. Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). ASCO GU Symposium. 2013 Feb. Abstract no. 75.

20. Singh PK, Preus L, Hu Q, Yan L, Long M, Morrison C, Nesline M, Johnson C, Koochekpour S, Kohli M, Liu S, Trump D, Campbell MJ, Sucheston LE. Serum expression levels of microRNA predict the risk of biochemical failure in prostate cancer. HGM 2013 and 21st Annual Congress of Genetics. 04/2013.

21. Parrilla-Castellar ER, Cheville JC, Kohli M, Sebo TJ, Jimenez RE. Immunohistochemical Evaluation of ERG Expression in Metastatic Carcinoma of the Prostate. United States & Canadian Academy of Pathology's 101st Annual Meeting. 2012 March 17-23.

22. Parrilla-Castellar ER, Cheville JC, Kohli M, Sebo TJ, Jimenez RE. Immunohistochemical evaluation of ERG expression in metastatic carcinoma of the prostate. Lab Invest. 2012 Feb; 92:233A.

23. Parrilla-Castellar ER, Cheville JC, Kohli M, Sebo TJ, Jimenez RE. Immunohistochemical evaluation of erg expression in metastatic carcinoma of the prostate. Mod Pathol. 2012 Feb; 25:233A.

24. Kohli M, Oberg AL, Mahoney DW, Riska SM, Zenka SM, Sahasrabudhe DM, Zhang S. Serum proteomis guided discovery of predictive biomarkers of response to androgen ablation (AA) in prostate cancer (abstract submitted . Am Soc Clin Oncol Genitourinary Cancers Symposium. 2012.

25. Kohli M, Oberg AL, Mahoney DW, Riska SM, Zhang Y, Zenka RM, Sahasrabudhe DM, Qin R, Carlson R, Zhang S. Serum proteomics and ingenuity pathway analysis (IPA)-guided discovery of response markers to androgen ablation (AA) in prostate cancer. J Clin Oncol. 2012; 30:2012.

26. Kohli M, Tindall DJ. Abstract CN08-01: Targeting the androgen receptor in castration-resistant prostate cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Nov 12-16, 2011.

27. Manish Kohli, Douglas Mahoney, High Chai, David Hillman, David Rider, Brian Costello, James Cerhan. Variation in UDP glucouronyltransferase (UGT) genes associated with prostate cancer mortality. 102nd AACR Annual Meeting. 2011.

Page 27: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

27

28. Parrilla-Castellar ER, Cheville JC, Kohli M, Sebo TJ, Jimenez RE. Evaluation of ERG expression

in metastatic carcinoma of the prostate (abstracted submitted). 2010 USCAP Annual Meeting. 2010.

29. Tilburt J, Kohli M, Bagniewski S, Shi Q, Morlan B, Shah N. Psa utilization, biochemical recurrence rates, and survival after initial definitive treatment for prostate cancer: descriptive results from a population-based cohort. J Gen Intern Med. 2009 Apr; 24(Suppl 1):150.

30. Kohli M, Rothberg PG, Schweitzer P, Sun Q, Ponnala L, Grills G, Sahasrabudhe D, Messing E, Joseph J, Wang W. The prognostic influence of inherited polymorphisms on prostate cancer outcomes. AACR Special Conference “Candidate Pathway and Whole Genome Scans” 2008.

31. Kohli M, Messing E, Feng C, Ricke E, Ricke W, Joseph J, Constantino A, Sahasrabudhe D. Serial plasma VEGF A & D in advanced stage prostate cancer patients undergoing hormonal and chemotherapy intervention ASCO. 2008.

32. Kohli M, Messing E, Schoen SR, Feng C, Joseph J, Constantino A, Vidyarao S, Sahasrabudhe D. A cross sectional study of angiopoietin-1 (Ang-1) in early and advanced prostate cancer. ASCO. 2008.

33. Kohli M, Rothberg P, Constantino A, Feng C, Messing E, Sahasrabudhe D. An exploratory analysis of the R250W polymorphism in the KLK2 gene as a prognostic marker in prostate cancer. AACR. 2007.

34. Kohli M, Kaushal V, Fan C. Vascular endothelial growth factor A and D and flt1/flk1/flt4 receptor

expression in metastatic lesions from prostate cancer (Abstract 4723). Proc Annu Meet Am Soc Clin Oncol. 2005.

35. Khan MA, Spencer HJ, Kaushal V, Kohli M. Prognostic value of plasma VEGF in advanced prostate cancer: an exploratory analysis (Abstract 4683). Proc Annu Meet Am Soc Clin Oncol. 2004.

36. Kohli M, Alikhan MA, Spencer HJ, Carter G. Phase I trial of intramuscular estradiol valerate in hormone refractory prostate cancer (Abstract 4726). Proc Annu Meet Am Soc Clin Oncol. 2004.

37. Kota M, Shah R, Greene G, Kohli M, James J, Gokden N. COX-2 expression in renal cell cancer (Abstract 9699). Proc Annu Meet Am Soc Clin Oncol. 2004.

38. Midathada M, Dennis R, Kaushal V, Kohli M. Role of androgen deprivation in EGFR and Her-2/neu gene expression patterns in prostate cancer (Abstract 9574). Proc Annu Meet Am Soc Clin Oncol. 2004.

39. Shah R, Bhattacharya S, Siegal E, Suva L, Kohli M. Differential serum protein expression in PSA-stable and PSA-rising hormone-sensitive advanced prostate cancer using SELD-TOF mass spectrometry (Abstract 4730). Proc Annu Meet Am Soc Clin Oncol. 2004.

40. Chiles W, Johnson DE, Mukunyadzi P, Spencer HJ, Kaushal V, Kohli M. Vascular endothelial cadherin as an anti-angiogenesis therapeutic target in prostate cancer. American Urology Association Regional Conference. 2003.

Page 28: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

28

41. Kaushal V, Mukunyadzi P, Mehta P, Kohli M. Stage-specific expression of lymphangiogenic markers in prostate cancer. ASCO. 2003.

42. Kohli M, Dennis R, Mukunyadzi P, Mehta P, Spencer HJ, Kaushal V. Molecular targets for anti-angiogenesis in prostate cancer. ASCO. 2003.

43. Midathada M, Shah R, Spencer HJ, Kohli M. Chemotherapy strategies in elderly prostate cancer patients. ASCO. 2003.

44. Kohli M, Kaushal V, Spencer HJ, Mehta P. Angiogenesis and coagulation pathway interactions in advanced prostate cancer. American Society of Hematology. 2002.

45. Kohli M, Kaushal V, Spencer HJ, Metha P. Plasminogen system association with angiogenesis in advanced prostate cancer. American Society of Hematology. 2002.

46. Kohli M, Kaushal V, Spencer HJ, Mehta P. Controlled study of circulating angiogenic markers in "hormone-escaping" advanced stage prostate cancer during androgen deprivation therapy (Abstract 10342). Proc Annu Meet Am Soc Clin Oncol. 2002.

47. Mehta P, Zent C, Safar M, Kohli M, Hammond N, Hutchins L. The Hematology-Oncology firm is a model program for providing comprehensive training and continuity of care. ACGME Abstract book, Chicago, 2001.

48. Kohli M, Coke P, Hauer-Jensen M, Hutchins L, Mehta P. Analysis of prostate specific antigen (PSA) based practice in elderly veterans’ population. 6th National VA Conference. 2001.

49. Vinson L, Coke P, Kohli M, Safar M, Zent C, Hutchins L, Mehta P. Do VA patients have adequate access to national cancer clinical trials. 6th National VA Conference. 2001.

50. Kohli M, Zent CS, Reynolds T, Spencer H, Fink LM. Prostate cancer activates coagulation: a controlled study of activation markers of coagulation in prostate cancer (Abstract 5180). International Society for Thrombosis and Hemostasis Annual Meeting. 2001.

51. Kohli M. Parenteral estrogen therapy in advanced prostate cancer: retrospective analysis of intramuscular estradiol valerate in "hormone refractory" prostate disease (Abstract 2407). Proc Annu Meet Am Soc Clin Oncol. 2001.

52. Kohli M, Fink LM, Chatta GS, Spencer HJ, Zent CS. Measurement of hypercoagulable states in progressive cancer of the prostate (Abstract 1471). Proc Annu Meet Am Soc Clin Oncol. 2000.

53. Kohli M, Chatta GS. Retrospective analysis of parenteral conjugated estrogen therapy in chemohormonal refractory advanced prostate cancer (Abstract 1327). Proc Annu Meet Am Soc Clin Oncol. 1999.

54. Kohli M, Schichman SA, Fink LM, Zent CS. Utilization of the HFE assay for hereditary hemochromatosis in Arkansas (Abstract 3049). Blood. 1998; 92(Suppl 1):17b.

55. Kohli M, Jazieh AR, Chatta GS, Ross SW. High-dose methotrexate and platinum-based chemotherapy in advanced stage urothelial cancer (Abstract 1292). Proc Annu Meet Am Soc Clin Oncol. 1997.

Page 29: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

29

Research Grants Awarded Active Grants Federal Principal Investigator Department of Defense: W81XWH-15-1-0634-01 Abiraterone Acetate Pharmacogenomics. Funded by Department of Defense 10/01/2015 - 09/30/2018 (Effort--Year 1- 15%; Years 2 & 3: 10% each)

Program Director / Principal Investigator (Mayo Clinic) Genetic determinants of gene expression phenotypes in aggressive prostate cancer. Funded by National Cancer Institute. (R01 CA 157881) 10/01/2011 - 07/31/2016 (Effort: Years 1- 5; 5%) Program Director / Principal Investigator Abiraterone Acetate Pharmacogenomics. Funded by Minnesota Partnership for Biotechnology and Medical Genomics. (MNP #14.37) 02/01/2015 - 02/28/2017 (FTE: Year 1: 18%; Year 2: 15%)

Co-Investigator Inhibiting serine protease-induced prostate cancer progression. Funded by National Cancer Institute. (R01 CA 154387) 04/01/2013 - 03/31/2018 (FTE: Years 3, 4: 5%)

Foundation

Co-Program Director / Principal Investigator Targeting Aberrant AR-FL and AR-V Expression and Activity to Overcome Therapy Resistance in Metastatic Castration-Resistant Prostate Cancer Funded by Prostate Cancer Foundation. Challenge Award 2015 7/1/2015 - 6/30/2017 (FTE: Years 1, 2: 10 % per year) Program Director / Principal Investigator Exploiting an actionable germline biomarker of castration-resistant prostate cancer. Funded by Prostate Cancer Foundation. Challenge Award 2014 12/24/2014 - 12/23/2016 (FTE: Years 1, 2: 7 % per year)

Page 30: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

30

Program Director / Principal Investigator Richard M. Schulze Family Foundation For Awards in Cancer Research Medically Optimized genome enhanced ThErapy (PROMOTE) in advanced prostate cancer 02/01/2012 – 1/31/2016. (FTE: Years 1 - 3: 10 % per year) Intramural Grants 1. Mayo Clinic (Center for Individualized Medicine) Program Director / Principal Investigator Investigator Initiated MC1351: PROstate cancer Medically Optimized genome enhanced ThErapy (PROMOTE) Funded for analysis and drug support by Janssen Research and Development, LLC. (Protocol Number 212082PCR4017 / MC1351) 02/01/2012 – 1/31/2017. (FTE: Years 1-3: 15 % per year; Year 4: 5%)

2. Principal Investigator - A feasibility study for ultrasensitive detection of target micro- RNAs in small volume blood samples of advanced stage prostate and kidney cancer patients (Multi-Institutional study). $220,000. December 2015-July 2017. (Center for Individualized Medicine) (FTE: 10%)

Investigator Initiated Industry Supported Program Director / Principal Investigator Investigator Initiated Pilot study to assess feasibility of profiling serum and whole blood-extracted RNA from prostate cancer patients for transcriptome-wide analysis. Funded by GenomeDx Biosciences Inc. 11/01/2013 - 04/30/2014

Industry

Program Director / Principal Investigator Amendment #3 - Replacement - CRPC2 A Multinational Phase III, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer. Funded by Medivation, Inc. (Protocol CRPC2) 09/15/2009 - 09/14/2012 Program Director / Principal Investigator Amendment #3 - Replacement - (Open Label Portion) CRPC2 A Multinational Phase III, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer in: Amendment #3 - Replacement - CRPC2 A Multinational Phase III, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer. Funded by Medivation, Inc. (Protocol CRPC2) 09/15/2009 - 09/14/2012

Page 31: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

31

Program Director / Principal Investigator MDV3100-03 Medivation in: Amendment #2 (Replacement) MDV3100-03, PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer. Funded by Medivation, Inc. (Protocol MDV3100-03) 01/01/2011 - 12/31/2012 Program Director / Principal Investigator MCR C21004, A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy Naïve Metastatic Castration-Resistant Prostate Cancer. Funded by Millennium Pharmaceuticals, Inc. (Protocol No. C21004 / Agreement No. 223475) 02/01/2011 - 01/31/2013 Program Director / Principal Investigator IMCL CP20-0902 in: IMCL CP20-0902: An Open-Label, Multicenter, Randomized Ph2 Study Eval the Safety & Efficacy of Docetaxel in Comb w/ Ramucirumab w/o Investgtl Thrpy as 2-line Thrpy in Pts w/ Lcaly Adv or Met Trans Cell Carcinoma of Blder/ Urethra/Ureter/Renal Pelvis. Funded by ImClone Systems. (Protocol CP20-0902) 02/03/2011 - 02/02/2013 11/01/2013 - 10/31/2015 Program Director / Principal Investigator ARMOR2: A 2 PART, PHASE 2 TRIAL OF GALETERONE IN THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER. Funded by Tokai Pharmaceuticals, Inc. (Protocol TOK-200-10) 03/01/2014 - 02/29/2016

Program Director / Principal Investigator

"ACT" B-701-U21 in: "ACT" B-701-U21: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment Metastatic Urothelial Carcinoma in Subjects who have Relapsed After Standard Therapy. Funded by BioClin Therapeutics, Inc. (B-701-U21) 05/27/2015 - 05/26/2018 Program Director / Principal Investigator PROstate cancer Medically Optimized genome enhanced ThErapy (PROMOTE). Funded by Richard M. Schulze Family Foundation Awards in Cancer Research. 02/01/2013 - 01/31/2016 Program Director / Principal Investigator Germline predictors of prognosis in metastatic Castrate Resistant Prostate Cancer (CRPC). Funded by SGP - Small Grants Program <$10K. 03/13/2014 - 03/12/2016

Page 32: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

32

Completed Grants

Federal Principal Investigator Role of thrombin-mediated angiogenesis in metastatic prostate cancer. Funded by National Cancer Institute. 06/2002 - 06/2004 Program Director / Principal Investigator Proteomics - Based Approach for Identifying Predictive Factors in Prostate Cancer Androgen Deprivation Therapy in: A Proteomics Approach for Identifying Predictive Factors to Androgen Deprivation. Funded by National Cancer Institute. (R21 CA 133536) 07/2009 - 06/2011 Co-Investigator Genetic determinants of gene expression phenotypes in aggressive prostate cancer. Funded by National Cancer Institute. (R01 CA 157881) 09/2011 Co-Project Leader Fatemi - Prostate Imaging by Vibro-acoustography in: SPORE in Prostate Cancer. Funded by National Cancer Institute. (P50 CA 91956) 09/2006 - 08/2013

Foundation

Principal Investigator Hypercoaguable states in advanced prostate cancer. Funded by UAMS Reynold's Center on Aging (Pilot Grant). 03/1999 - 06/2002 Principal Investigator Phase I pilot trial of the effects of parenteral estrogen therapy on the coagulation system of patients with advanced stage prostate cancer. Funded by Biomedical Research Foundation. (FDA IND #65-446) 12/2001 Principal Investigator Study of angiogenic growth factors in advanced prostate cancer. Funded by American Cancer Society Institutional Research Grant. (IRG 91-021-08) 12/2001

Page 33: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

33

Co-Investigator Arrayed imaging reflectometry based detection of circulatory peptides in prostate cancer. Funded by CTSI Noval Clinical and Translational Methodologies Pilot Project, University of Rochester (Pilot Grant). 05/2007 - 06/2008 Industry Principal Investigator Randomized controlled trial of osteoporosis prevention in racially diverse advanced stage prostate cancer patients. Funded by Novartis. 03/2003 - 06/2006 Program Director / Principal Investigator UMCC2005.145, Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma in: UMCC2005.145, Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma,. Funded by Pfizer Inc. (Protocol # SU011248) 03/2009 - 03/2011 Program Director / Principal Investigator OGX-011-10: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-Line Therapy in Men with Castrate Resistant Prostate Cancer in: OGX-011-10: A randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer. Funded by OncoGenex Technologies. (OGX-011-10) 11/2009 - 10/2011 Program Director / Principal Investigator OGX-011-11 in: OGX-011-11, A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer. Funded by TEVA Pharmaceutical. (Protocol OGX-011-11) 12/2010 - 11/2012

Page 34: Manish Kohli, MD Professor of Oncology Consultant (507 ... · Manish Kohli, MD . Professor of Oncology . Mayo Clinic College of Medicine . Consultant . Division of Oncology . Department

34

Patents

1. Predicting Responses to Androgen Deprivation Therapy Inventors: Offer, Steven M.; Cerhan, James R.; Mahoney, Douglas W.; Kohli, Manish. US 13821807 03/2013

2. Predicting Responses to Androgen Deprivation Therapy Inventors: Zenka, Roman M.; Mahoney, Douglas W.; Oberg, Ann L.; Kohli, Manish; Zhang, Sheng; Zhang, Yuji. US 2013024465 02/2013

3. Predicting Responses to Androgen Deprivation Therapy Inventors: Kohli, Manish; Oberg, Ann L.; Mahoney, Douglas W.; Zenka, Roman M.; Zhang, Yuji; Zhang, Sheng. US 61593702 02/2012

4. Predicting Responses to Androgen Deprivation Therapy Inventors: Mahoney, Douglas W.; Kohli, Manish; Cerhan, James R.; Offer, Steven M. US 2011050836 09/2011

5. Predicting Responses to Androgen Deprivation Therapy Inventors: Kohli, Manish; Mahoney Douglas W.; Cerhan, James R.; Offer, Steven M. EP 118241298 09/2011

6. Prediction responses to Androgen Deprivation Therapy Inventors: Kohli, Manish; Mahoney, Douglas W.; Cerhan, James R.; Offer, Steven M. US 61380786--09/2010